Trial Profile

Pan tumour trial of COX-inhibitor and immune checkpoint blockade

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Celecoxib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Male breast cancer; Non-small cell lung cancer; Renal cell carcinoma; Triple negative breast cancer
Focus Therapeutic Use
Acronyms LION

Most Recent Events

14 May 2024 Planned End Date changed from 3 Jun 2026 to 7 May 2027.
26 Apr 2023 Status changed from not yet recruiting to recruiting.
14 Oct 2022 The recruitment start date was changed from 31/10/2022 to 31/01/2023.The recruitment end date was changed from 10/12/2023 to 01/01/2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com